Login to Your Account

Cypress Partners Milnacipran In Union Worth Up To $250M

By Aaron Lorenzo

Monday, January 12, 2004
Cypress Bioscience Inc. could receive between $200 million and $250 million through a deal for milnacipran, its Phase III product for fibromyalgia syndrome, a common cause of chronic and widespread pain. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription